LifeVantage Corporation (NASDAQ: LFVN) shares continued their upward trajectory during the fourth trading session on Friday. LifeVantage stock experienced a noteworthy surge of 15.13% to conclude the weekend session at $5.63. This positive momentum initiated on Monday of the previous week, coinciding with LFVN’s successful reelection of all seven incumbent directors to its board.
LifeVantage (LFVN) has officially disclosed the certified results of its fiscal year 2024 annual meeting of stockholders, as validated by the independent inspector of elections. The outcomes affirm the shareholders’ reelection of all seven LFVN incumbent directors, marking a substantially heightened turnout compared to past LifeVantage annual stockholder gatherings.
LFVN expresses confidence in possessing the optimal Board and leadership team to effectively execute its LV360 strategy, ensuring profitable growth and substantial value for stockholders. Additionally, the results indicate shareholders’ approval of all other proposals presented at the Annual Meeting, including the stockholders’ rights plan.
In a recent development, LFVN introduced the TrueScience TrueRenew Daily Firming Complex, an innovative cosmetic retinol alternative that is both cleaner and gentler. This comprehensive product, scientifically proven to address 11 visible signs of aging, signifies a new chapter for the TrueScience Activated Skincare line.
TrueRenew is strategically crafted to complement the internal activation power of Protandim Nrf2 Synergizer and TrueScience Liquid Collagen, constituting the top-selling product stack, Healthy Glow Essentials. With a keen eye on LifeVantage Consultant businesses, TrueRenew responds to the burgeoning global retinol market, projected to reach $1.79 billion by 2030, with an anticipated CAGR of 3.8% from 2023 to 2030.
The product exemplifies LifeVantage’s adeptness in developing innovative solutions, harnessing proprietary expertise with activation. TrueRenew stands out as a unique formula, delivering visibly lifted, firmer, and smoother-looking skin without the drawbacks associated with traditional retinol use. Clinical validation comes from a 6-week third-party clinical trial overseen by a board-certified dermatologist, reinforcing the tangible benefits of TrueRenew.